Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Next Previous
Trial Profile

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Datopotamab deruxtecan (Primary) ; Trastuzumab-deruxtecan (Primary) ; Valemetostat (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 04 Sep 2024 According to a Daiichi Sankyo media release, clinical data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress, September 9 10:45 - 12:00 pm
  • 03 Jul 2024 Study design discussed in 60th Annual Meeting of the American Society of Clinical Oncology
  • 14 Jun 2024 Number of treatment arms are increased from 4 to 6 by the addition of 2 more experimental arms, namely- Part 1: Dose Escalation (Sub-protocol A) and Part 2: Dose Expansion (Sub-protocol A). Advanced HER2 low breast cancer and Gastroesophageal junction cancer are newly added to indications.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top